CO COLL Collegium Pharmaceutical, Inc. Loading... : Bullish and Bearish Analyst Opinions

The business generates ~$290M in owner earnings with near-zero capex, trades at 5.6x enterprise value, and has a 61% gross margin with 20% revenue CAGR over five years. The market prices the stock as if the patent cliffs and debt will destroy value soon, but the cash flow can de-lever quickly, and the ADHD portfolio is growing fast + pain revenue stabilizing via profit-sharing deals. At $35 with an estimated intrinsic value of $122 (70% margin of safety), the stock offers a compelling risk/reward for value investors willing to hold through finite patent lives. Faster-than-expected generic erosion in pain portfolio; debt service constraints if revenue drops; FDA/regulatory changes; management capital allocation missteps.